{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T20:34:37Z","timestamp":1794688477881,"version":"4.9.1"},"reference-count":112,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.clindermatol.2011.03.015","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T19:23:41Z","timestamp":1323372221000},"page":"95-102","source":"Crossref","is-referenced-by-count":19,"title":["Treatment of subepidermal immunobullous diseases"],"prefix":"10.1016","volume":"30","author":[{"given":"Donna A.","family":"Culton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2011.03.015_bb0005","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.1965.03080210026006","article-title":"Autoantibodies in pemphigus vulgaris: response to an intercellular substance of epidermis","volume":"192","author":"Beutner","year":"1965","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1001\/jama.1967.03120220053008","article-title":"Basement zone antibodies in bullous pemphigoid","volume":"200","author":"Jordon","year":"1967","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-195302000-00001","article-title":"Pemphigus","volume":"32","author":"Lever","year":"1953","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0020","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1172\/JCI117826","article-title":"The role of complement in experimental bullous pemphigoid","volume":"95","author":"Liu","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1172\/JCI119639","article-title":"A major role for neutrophils in experimental bullous pemphigoid","volume":"100","author":"Liu","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archderm.143.2.249","article-title":"The role of IgE anti-basement membrane zone autoantibodies in bullous pemphigoid","volume":"143","author":"Woodley","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0035","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/sj.jid.5700681","article-title":"IgE basement membrane zone antibodies induce eosinophil infiltration and histological blisters in engrafted human skin on SCID mice","volume":"127","author":"Zone","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0040","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0045","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/archderm.1977.01640080045002","article-title":"Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy","volume":"113","author":"Ahmed","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0050","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJM199511303332207","article-title":"Management of acquired bullous skin diseases","volume":"333","author":"Fine","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000248663","article-title":"Clinical, histological and immunological studies in 50 patients with bullous pemphigoid","volume":"176","author":"Hadi","year":"1988","journal-title":"Dermatologica"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0060","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(89)70058-X","article-title":"Treatment of bullous pemphigoid with topical clobetasol propionate","volume":"20","author":"Westerhof","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0070","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJM200207113470215","article-title":"Oral and topical corticosteroids in bullous pemphigoid","volume":"347","author":"Bystryn","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0080","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archderm.139.6.813","article-title":"Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid","volume":"139","author":"Chu","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0085","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2133.2004.05835.x","article-title":"The application of topical tacrolimus in vesicular pemphigoid","volume":"150","author":"Chuh","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0090","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1365-2133.2003.05611.x","article-title":"Topical tacrolimus therapy for localized bullous pemphigoid","volume":"149","author":"Ko","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000077319","article-title":"Localized childhood vulval pemphigoid treated with tacrolimus ointment","volume":"208","author":"Lebeau","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0100","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1517\/14656566.7.17.2403","article-title":"Bullous pemphigoid treatment review","volume":"7","author":"Patton","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2133.2002.04835.x","article-title":"Guidelines for the management of bullous pemphigoid","volume":"147","author":"Wojnarowska","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0110","first-page":"518","article-title":"[Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study]","volume":"120","author":"Dreno","year":"1993","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0115","first-page":"925","article-title":"[Treatment of bullous pemphigoid with prednisolone only: 0.75 mg\/kg\/day versus 1.25 mg\/kg\/day. A multicenter randomized study]","volume":"111","author":"Morel","year":"1984","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0120","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archderm.1984.01650450039014","article-title":"High-dose methylprednisolone in the treatment of bullous pemphigoid","volume":"120","author":"Siegel","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0125","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2133.1979.tb11881.x","article-title":"The events leading to the death of patients with pemphigus and pemphigoid","volume":"101","author":"Savin","year":"1979","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archderm.138.3.385","article-title":"A systematic review of treatments for bullous pemphigoid","volume":"138","author":"Khumalo","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0135","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","article-title":"Azathioprine plus prednisone in treatment of pemphigoid","volume":"2","author":"Burton","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00008571-199902000-00006","article-title":"The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations","volume":"9","author":"Collie-Duguid","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0150","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archderm.1995.01690140077013","article-title":"The role of genetic variation in thiopurine methyltransferase activity and the efficacy and\/or side effects of azathioprine therapy in dermatologic patients","volume":"131","author":"Snow","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0155","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0190-9622(00)90176-2","article-title":"Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case","volume":"42","author":"Tavadia","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0160","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/00007890-199606150-00023","article-title":"Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation","volume":"61","author":"Cummins","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0165","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1345\/aph.1L077","article-title":"Azathioprine-induced warfarin resistance","volume":"42","author":"Vazquez","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(97)80092-X","article-title":"Bullous pemphigoid treated with mycophenolate mofetil","volume":"349","author":"Bohm","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0175","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1001\/archderm.135.6.724","article-title":"Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy","volume":"135","author":"Grundmann-Kollmann","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0180","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0190-9622(99)70084-8","article-title":"Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases","volume":"40","author":"Grundmann-Kollmann","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0190-9622(98)70334-2","article-title":"Successful therapy for bullous pemphigoid with mycophenolate mofetil","volume":"39","author":"Nousari","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0190","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0195","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2174\/157016309789869065","article-title":"Current treatment of autoimmune blistering diseases","volume":"6","author":"Kasperkiewicz","year":"2009","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0200","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2133.1997.tb01131.x","article-title":"Severe bullous pemphigoid responsive to pulsed intravenous dexamethasone and oral cyclophosphamide","volume":"137","author":"Dawe","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0205","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.1996.tb06329.x","article-title":"Successful treatment of bullous pemphigoid with pulsed intravenous cyclophosphamide","volume":"134","author":"Itoh","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0210","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0190-9622(99)70156-8","article-title":"Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid","volume":"40","author":"Heilborn","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0215","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1001\/archderm.139.11.1506-b","article-title":"Methotrexate for bullous pemphigoid: preliminary study","volume":"139","author":"Bara","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0220","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archderm.138.9.1255","article-title":"Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases","volume":"138","author":"Dereure","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1365-2133.2009.09246.x","article-title":"Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid","volume":"161","author":"Gurcan","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0230","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archderm.144.5.612","article-title":"A retrospective analysis of patients with bullous pemphigoid treated with methotrexate","volume":"144","author":"Kjellman","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1523-1747.ep12555654","article-title":"Dapsone suppresses integrin-mediated neutrophil adherence function","volume":"98","author":"Booth","year":"1992","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0240","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/jlb.62.6.827","article-title":"Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction","volume":"62","author":"Debol","year":"1997","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0245","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.4049\/jimmunol.137.4.1305","article-title":"Selective inhibition of human neutrophil chemotaxis to N-formyl-methionyl-leucyl-phenylalanine by sulfones","volume":"137","author":"Harvath","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11310740-000000000-00000","article-title":"Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data","volume":"10","author":"Gurcan","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0255","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D330M4B5KR","article-title":"Dapsone","volume":"8","author":"Wolf","year":"2002","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0260","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2133.1993.tb00476.x","article-title":"Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance","volume":"129","author":"Coleman","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0265","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2230.1995.tb02672.x","article-title":"Dapsone-induced motor peripheral neuropathy in pemphigus foliaceus","volume":"20","author":"Rhodes","year":"1995","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0270","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: overview and update","volume":"45","author":"Zhu","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0275","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1001\/archderm.1986.01660180076019","article-title":"The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report","volume":"122","author":"Berk","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0280","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0285","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2133.1995.tb02498.x","article-title":"Bullous pemphigoid successfully controlled by tetracycline and nicotinamide","volume":"133","author":"Kolbach","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0290","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(84)92565-0","article-title":"Plasma exchange in bullous pemphigoid","volume":"2","author":"Roujeau","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0295","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1046\/j.1365-4362.2000.00876.x","article-title":"Plasmapheresis as a steroid saving procedure in bullous pemphigoid","volume":"39","author":"Egan","year":"2000","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1473-0502(02)00095-2","article-title":"Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid","volume":"28","author":"Mazzi","year":"2003","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0305","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00128071-200405030-00003","article-title":"Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view","volume":"5","author":"Ruetter","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0310","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJM199901213400311","article-title":"Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases","volume":"340","author":"Yu","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0315","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2133.1995.tb02631.x","article-title":"Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients","volume":"133","author":"Beckers","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0320","doi-asserted-by":"crossref","first-page":"964","DOI":"10.7326\/0003-4819-103-6-965_1","article-title":"Bullous pemphigoid and intravenous gammaglobulin","volume":"103","author":"Godard","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0325","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.1365-2133.1999.02817.x","article-title":"High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases","volume":"140","author":"Harman","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0330","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(89)80148-3","article-title":"High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid","volume":"20","author":"Tappeiner","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1067\/mjd.2000.112288","article-title":"Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data","volume":"44","author":"Engineer","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0340","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0345","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0350","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1056\/NEJMc063290","article-title":"Rituximab for pemphigus vulgaris","volume":"356","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0355","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/annonc\/mdn046","article-title":"A new approach on bullous pemphigoid therapy","volume":"19","author":"Saouli","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0360","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0365","unstructured":"Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0370","first-page":"1","article-title":"Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the initial use to 2007","volume":"5","author":"Peterson","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0375","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0380","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0385","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1525-1470.2008.00751.x","article-title":"Severe bullous pemphigoid in an infant\u2014successful treatment with rituximab","volume":"25","author":"Schulze","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0390","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1038\/sj.jid.5700958","article-title":"A pathogenic role for IgE in autoimmunity: bullous pemphigoid IgE reproduces the early phase of lesion development in human skin grafted to nu\/nu mice","volume":"127","author":"Fairley","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0395","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1046\/j.1365-4362.1999.00813.x","article-title":"Linear IgA bullous dermatosis","volume":"38","author":"Egan","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0400","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0738-081X(00)00189-9","article-title":"Treatment of subepidermal immunobullous diseases","volume":"19","author":"Wojnarowska","year":"2001","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0405","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2230.1991.tb00336.x","article-title":"Chronic bullous dermatosis of childhood\u2014clinical and immunological features seen in African patients","volume":"16","author":"Aboobaker","year":"1991","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0410","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0001-7310(06)73463-9","article-title":"[Linear IgA bullous dermatosis of adults treated with colchicine]","volume":"97","author":"Hernandez-Machin","year":"2006","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0415","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1525-1470.1999.99015.x","article-title":"Treatment of linear IgA bullous dermatosis of childhood with colchicine","volume":"16","author":"Ang","year":"1999","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0420","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/archderm.1984.01650430150027","article-title":"Linear IgA bullous dermatosis. Successful treatment with colchicine","volume":"120","author":"Aram","year":"1984","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0425","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-4362.1997.00033.x","article-title":"Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood","volume":"36","author":"Banodkar","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0430","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0190-9622(09)80120-5","article-title":"Successful treatment of chronic bullous dermatosis of childhood with colchicine","volume":"30","author":"Zeharia","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0435","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/j.1365-2230.2007.02509.x","article-title":"Linear IgA bullous dermatosis responsive to trimethoprim-sulfamethoxazole","volume":"32","author":"Peterson","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0440","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1468-3083.2007.02315.x","article-title":"Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis","volume":"22","author":"Dauendorffer","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0445","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/09546630801958246","article-title":"Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium","volume":"19","author":"Marzano","year":"2008","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0450","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000279318","article-title":"Linear IgA disease: successful application of immunoadsorption and review of the literature","volume":"220","author":"Kasperkiewicz","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0455","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaad.2006.06.029","article-title":"High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases","volume":"56","author":"Segura","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0460","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0190-9622(99)70504-9","article-title":"Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy","volume":"40","author":"Khan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0465","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1468-3083.2009.03188.x","article-title":"Guidelines for the diagnosis and treatment of dermatitis herpetiformis","volume":"23","author":"Caproni","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0470","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1600-0609.2005.00545.x","article-title":"Dapsone for chronic idiopathic thrombocytopenic purpura in children and adults\u2014a report on 90 patients","volume":"75","author":"Damodar","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0475","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1111\/j.1600-6143.2005.01079.x","article-title":"Complications related to dapsone use for pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients","volume":"5","author":"Lee","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0480","first-page":"268","article-title":"Severe dapsone hypersensitivity syndrome","volume":"16","author":"Sener","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0485","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jclinane.2004.10.011","article-title":"Presentation of dapsone-induced methemoglobinemia in a patient status post small bowel transplant","volume":"17","author":"Talarico","year":"2005","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0490","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2133.1989.tb08218.x","article-title":"Sulphamethoxypyridazine for dermatitis herpetiformis, linear IgA disease and cicatricial pemphigoid","volume":"121","author":"McFadden","year":"1989","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0495","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1440-0960.2005.00152.x","article-title":"Sulfasalazine and dermatitis herpetiformis","volume":"46","author":"Willsteed","year":"2005","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0500","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2133.1994.tb08557.x","article-title":"25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis","volume":"131","author":"Garioch","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0505","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0738-081X(91)90033-H","article-title":"Details of the gluten-free diet for the patient with dermatitis herpetiformis","volume":"9","author":"Rottmann","year":"1991","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0510","doi-asserted-by":"crossref","unstructured":"Ishii N, Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita: what's new? J Dermatol 37:220-30.","DOI":"10.1111\/j.1346-8138.2009.00799.x"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0515","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004056","article-title":"Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita","author":"Kirtschig","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0520","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1067\/mjd.2001.113693","article-title":"Emerging treatment for epidermolysis bullosa acquisita","volume":"44","author":"Engineer","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0525","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0190-9622(96)90013-4","article-title":"Colchicine for epidermolysis bullosa acquisita","volume":"34","author":"Cunningham","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0530","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00375841","article-title":"Epidermolysis bullosa acquisita\u2014successful treatment with colchicine","volume":"286","author":"Megahed","year":"1994","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0535","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1346-8138.2005.tb00727.x","article-title":"Remission of recalcitrant epidermolysis bullosa acquisita (EBA) with colchicine monotherapy","volume":"32","author":"Arora","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0540","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0190-9622(93)70189-Z","article-title":"Epidermolysis bullosa acquisita: efficacy of high-dose intravenous immunoglobulins","volume":"29","author":"Meier","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0545","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archderm.1990.01670270071012","article-title":"Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis","volume":"126","author":"Gupta","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0550","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archderm.135.8.954","article-title":"Mucosal morbidity in patients with epidermolysis bullosa acquisita","volume":"135","author":"Luke","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0555","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2230.1993.tb01028.x","article-title":"Epidermolysis bullosa acquisita\u2014a case with upper airways obstruction requiring tracheostomy and responding to cyclosporin","volume":"18","author":"Clement","year":"1993","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clindermatol.2011.03.015_bb0560","first-page":"111","article-title":"Review and update of epidermolysis bullosa fsacquisita","volume":"7","author":"Woodley","year":"1988","journal-title":"Semin Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11000915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X11000915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T16:27:57Z","timestamp":1686500877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X11000915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":112,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0738081X11000915"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2011.03.015","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}